Quantum SI (QSI)

Executive Summary

Quantum SI is a pioneering life sciences company commercializing the first single-molecule protein sequencing platform. Its flagship Platinum Pro benchtop instrument enables real-time, high-resolution proteomic analysis with a simplified workflow, democratizing access to protein-level insights. This technology addresses a critical gap in the post-genomic era, where proteins are the functional drivers of biology but remain challenging to study at scale. Quantum SI’s platform has the potential to accelerate biomarker discovery, therapeutic development, and fundamental research by providing researchers with unprecedented direct access to protein sequences. The company has a strong intellectual property portfolio and a path to commercialization, targeting academic and pharmaceutical customers. With a current valuation of approximately $194 million and public listing (QSI), Quantum SI offers a high-risk, high-reward opportunity. Near-term catalysts include product enhancements, expanding commercial partnerships, and progress toward clinical applications. If successful, Quantum SI could become a key enabler of proteomics, analogous to what next-generation sequencing did for genomics.

Upcoming Catalysts (preview)

• Q4 2026Commercial Partnership or Collaboration with Major Pharma60% success
• Q3 2026Launch of Platinum Pro Product Enhancement or New Consumables70% success
• Q2 2027FDA Clearance for Clinical Research Use or Diagnostic Application40% success